Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy

AIDS

Volumn 13, Issue 8, 1999, Pages

  Harrigan, P Richard ^a,c   Whaley, Mark ^a   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; HAART; HIV RNA levels

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DEVICE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; INTOXICATION; KINETICS; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; TUBE; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0033004630     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00001     Document Type: Article

References (24)

1. Hogg SR, O'Shaughnessy MV, Gataric N, et al. Decline in deaths due to new antiretrovirals. Lancet 1997, 349:1294.
2. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
3. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998, 280:35-41.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
5. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 307:108-191.
6. Ho D Toward HIV eradication or remission: the tasks ahead. Science 1998, 280:1866-1867.
7. Wong JK, Hezareh M, Guthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278: 1291-1295.
8. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
9. Chun T-W, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13 193-13 198.
10. Ho D, Neumann AU, Perelson AS, Chen W, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
11. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
12. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho D HIV-1 dynamics in vivo: virion clearance rate, infected life-span, and viral generation time. Science 1996, 271:1582-1586.
13. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J infect Dis 1995, 171:1411-1419.
14. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998; 72:5154-5164.
15. Montaner JS, Harris M, Mo T, Harrigan PR Rebound of plasma HIV viral load following prolonged suppression with combination therapy [letter]. AIDS 1998, 12:1398-1399.
16. Jubault V, Burgard M, Le Corfec E, et al. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy [letter]. AIDS 1998 12:2358-2359.
17. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV infected patients with didanosine and hydracarbamide. Lancet 1997, 350:635-636.
18. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998. 36:2964-2969.
19. Kwok S, Sninsky J, Christopherson C, Krowka JF, Haynes S. Quantification of HIV-1 proviral DNA. XII International Conference on AIDS, Geneva, June 1998 [abstract 42172]
20. de Gruttola V, Hughes M, Gilbert P, Phillips A Trial design in the era of highly effective antiviral drug combinations for HIV infection. AIDS 1998, 12 (suppl A):S149-S156.
21. de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84.
22. Lafeuillade A, Chollet L, Hittinger G, et al. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. J Infect Dis 1998, 177:235-238.
23. Kaufmann GR, Cunningham P, Kelleher AD, et al. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. J Infect Dis 1998, 178:1812-1815.
24. Neumann AU, Tubiana R, Calvez V, et al. Multi-phasic HIV decline following triple drug antiviral therapy is correlated with viral rebound dynamics during therapy interruption. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998 [abstract 517].